- An adapted European Society for Medical Oncology (ESMO) guideline for the diagnosis, treatment, and follow-up of NSCLC includes specific recommendations for the treatment of patients of Asian ancestry.
- The adaptation is detailed in a consensus statement from oncology experts representing Korea, China, India, Japan, Malaysia, Singapore, and Taiwan.
Why this matters
- The adapted guidelines include changes reflecting differences related to ethnicity, cancer biology, and standard practices in participating Asian countries.
- The panel added a new recommendation for the consolidation administration of durvalumab 1-42 days after the end of chemoradiotherapy (10 mg/kg every 2 weeks for up to 12 months).
- In patients with negative biopsy results following endobronchial and/or endoscopic ultrasound, alternative methods to mediastinoscopy may be used if it is unavailable.
- A multidisciplinary assessment, especially for determination of resectability, is recommended.
- Carboplatin monotherapy may be considered in combination with radiation for patients >70 years with stage III disease.
- The management of radiation toxicities may require more frequent follow-up during the first year.